Zeng L et al. First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer. Med. 2024 Mar.
[1]Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications[J]. Lancet Oncol. 2012 Jan;13(1):e23-31. Epub 2011 Jul 19. Erratum...
Inframe insertions of three or more base pairs in exon 20 of the epidermal growth factor receptor (gene were among the firstmutations to be identified as oncogenic drivers in non-small cell lung cancer (NSCLC). However, unlike the classicalL858R point mutation or exon 19 deletions, which ...
[5]AssessinganOralEGFRInhibitor,YK-209AinPatientsWhoHaveAdvancedNon-smallCellLungCancerWithEGFR(YK-029A-101) YK-029AasFirst-LineTreatmentVersusPlatinum-BasedChemotherapyforNon-SmallCellLungCancer(NSCLC)WithEGFR exon 20insertionMutations(YK-029A-301) YK-029AinTreatmentSideEffectsandTreatment-ICHGCP编辑...
舒沃替尼在铂预处理的EGFR 20ins突变非小细胞肺癌患者中显示出有希望的抗肿瘤疗效。随着研究人员的不断探索,相信很快就能有新的药物获批上市,为非小细胞肺癌患者带来新的治疗选择。 参考资料 1.A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon ...
EGFR常见突变包括exon 19del和exon 21 L858R突变,约占所有EGFR突变的80%～85%,其余15%～20%的EGFR突变称为罕见突变。在罕见突变中,以EGFR exon 20ins突变最常见,约占整体的9%左右,同时也占所有EGFR exon 20突变的50%左右。 EGFR exon 20突变不仅在NSCLC中可见,还可以发生在其他瘤种中。TCGA(The Cancer Genom...
Amivantamab (JNJ-61186372), an anti–EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion-mutated non–small cell lung cancer. (Park K et al. 2020 ASCO annual meeting. Abstract 9512.)Newsletter Stay up to date on the most recent and practice-changing oncology data Subscribe...
[1]Meador CB, Sequist LV, Piotrowska Z. Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates. Cancer Discov. 2021 Sep;11(9):2145-2157. doi: 10.1158/2159-8290.CD-21-0226. Epub 2021 Jul 23. PMID: 34301786. ...
EGFR ex20ins的突变形式有很多,至今发现超过100种不同的突变形式,给治疗造成了很大难度。而且EGFR ex20ins会在其C螺旋结构附近形成一个“楔子”,形成刚性、不易弯曲的结构,将EGFR“锁定”在活性状态。目前常见的EGFR TKI很难有效地结合到20号外显子编码的结构域上。一项发表在《肺癌》(Lung Cancer)杂志上的真实...
Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer:Recent Advances and Clinical Updates. Cancer Discov. 2021 Sep;11(9):2145-2157. 【3】 Park K, Haura E B, Leighl N B, et al. Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on ...